ArticleFrontiers in genetics2015
Changes in expression of the long non-coding RNA FMR4 associate with altered gene expression during differentiation of human neural precursor cells.
Article in Frontiers in genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- LncRNAs Ride the Storm of Epigenetic Marks.Genes · 2025Review
- Correlation of FMR4 expression levels to ovarian reserve markers in FMR1 premutation carriers.Journal of ovarian research · 2024Article
- Evaluation of FMR4, FMR5 and FMR6 Expression Levels as Non-Invasive Biomarkers for the Diagnosis of Fragile X-Associated Primary Ovarian Insufficiency (FXPOI).Journal of clinical medicine · 2022Article
- Article
- Molecular Pathogenesis and Peripheral Monitoring of Adult Fragile X-Associated Syndromes.International journal of molecular sciences · 2021Review
- From Junk to Function: LncRNAs in CNS Health and Disease.Frontiers in molecular neuroscience · 2021Review
- Invited Review: Epigenetics in neurodevelopment.Neuropathology and applied neurobiology · 2020Review
- Exosomal FMR1-AS1 facilitates maintaining cancer stem-like cell dynamic equilibrium via TLR7/NFκB/c-Myc signaling in female esophageal carcinoma.Molecular cancer · 2019Article
- Long Noncoding RNA Can Be a Probable Mechanism and a Novel Target for Diagnosis and Therapy in Fragile X Syndrome.Frontiers in genetics · 2019Review
- Molecular mechanisms of long noncoding RNAs and their role in disease pathogenesis.Oncotarget · 2018Review
- Regulation of Adult Neurogenesis by Non-coding RNAs: Implications for Substance Use Disorders.Frontiers in neuroscience · 2018Review
- Long noncoding RNA and its contribution to autism spectrum disorders.CNS neuroscience & therapeutics · 2017Review
- Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration.Molecular and cellular neurosciences · 2017Review
- Differentially expressed circulating LncRNAs and mRNA identified by microarray analysis in obese patients.Scientific reports · 2016Article
- Human pluripotent stem cell models of Fragile X syndrome.Molecular and cellular neurosciences · 2016Review
- Structure Prediction: New Insights into Decrypting Long Noncoding RNAs.International journal of molecular sciences · 2016Review
- Where Environment Meets Cognition: A Focus on Two Developmental Intellectual Disability Disorders.Neural plasticity · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
CGG repeat expansions in the Fragile X mental retardation 1 (FMR1) gene are responsible for a family of associated disorders characterized by either intellectual disability and autism Fragile X Syndrome (FXS), or adult-onset neurodegeneration Fragile X-associated Tremor/Ataxia Syndrome. However, the FMR1 locus is complex and encodes several long non-coding RNAs, whose expression is altered by repeat expansion mutations. The role of these lncRNAs is thus far unknown; therefore we investigated the functionality of FMR4, which we previously identified. "Full"-length expansions of the FMR1 triplet repeat cause silencing of both FMR1 and FMR4, thus we are interested in potential loss-of-function that may add to phenotypic manifestation of FXS. Since the two transcripts do not exhibit cis-regulation of one another, we examined the potential for FMR4 to regulate target genes at distal genomic loci using gene expression microarrays. We identified FMR4-responsive genes, including the methyl-CpG-binding domain protein 4 (MBD4). Furthermore, we found that in differentiating human neural precursor cells, FMR4 expression is developmentally regulated in opposition to expression of both FMR1 (which is expected to share a bidirectional promoter with FMR4) and MBD4. We therefore propose that FMR4's function is as a gene-regulatory lncRNA and that this transcript may function in normal development. Closer examination of FMR4 increases our understanding of the role of regulatory lncRNA and the consequences of FMR1 repeat expansions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.